<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3898">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04593641</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P59 1.2</org_study_id>
    <secondary_id>2020-003165-19</secondary_id>
    <nct_id>NCT04593641</nct_id>
  </id_info>
  <brief_title>This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)</brief_title>
  <official_title>A Pilot Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Virology of CT-P59 in Patient With Mild Symptoms of SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group,&#xD;
      Single Ascending Dose Study to evaluate Safety, Tolerability and Virology of CT-P59 in&#xD;
      Patient with Mild Symptoms of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2)&#xD;
      Infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      'CT-P59 is a monoclonal antibody targeted against SARS-CoV-2 spike receptor binding protein&#xD;
      as a treatment for SARS CoV 2 infection. CT-P59 is currently being developed by the Sponsor&#xD;
      as a potential treatment for SARS-CoV-2 infection. In this study, safety, tolerability and&#xD;
      virology of CT-P59 will be evaluated in patient with mild symptoms of SARS-CoV-2 Infection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">December 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the preliminary safety and tolerability of CT-P59 up to Day 14 of the last enrolled subject</measure>
    <time_frame>Up to Day 14</time_frame>
    <description>Primary safety outcome&#xD;
Proportion of patients with Treatment-Emergent Adverse Events (TEAEs)&#xD;
Proportion of patients with Treatment-Emergent Serious Adverse Events (TESAEs)&#xD;
Proportion of patients with Treatment-Emergent Adverse Events of Special Interest (TEAESI; infusion related reactions including hypersensitivity/anaphylactic reaction)&#xD;
Proportion of patients with potential effects on the incidence of Antibody-Dependent Enhancement (ADE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the viral efficacy and characterization of SARS-CoV-2 viral isolates of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>1. The percentage of patients with positive/negative for quantitative Polymerase Chain Reaction (qPCR) and cell culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the viral efficacy and characterization of SARS-CoV-2 viral isolates of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>2. Duration (days) of viral shedding in nasopharyngeal swab specimens for qPCR and cell culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the viral efficacy and characterization of SARS-CoV-2 viral isolates of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>3. Area under the concentration-time curve of viral titers for qPCR and cell culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the viral efficacy and characterization of SARS-CoV-2 viral isolates of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>4. Actual results and change from baseline for viral shedding in nasopharyngeal swab specimens (titers) for qPCR and cell culture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>1. Proportion of patients with clinical recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>2. Proportion of patients requiring supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>3. Proportion of patients with intensive care unit transfer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>4. Proportion of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>5. Proportion of patients with all-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the efficacy of CT-P59</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>6. Proportion of patients with hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>1. Pharmacokinetic (PK) parameter: Area under the concentration-time curve from time zero to infinity (AUC0-inf) of CT-P59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>2. Pharmacokinetic (PK) parameter: Dose normalized AUC0-inf (AUC0-inf/Dose) of CT-P59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>3. Pharmacokinetic (PK) parameter: Area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last) of CT-P59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>4. Pharmacokinetic (PK) parameter: Dose normalized AUC0-last (AUC0-last/Dose) of CT-P59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>5. Pharmacokinetic (PK) parameter: Time to Cmax (Tmax) of CT-P59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>6. Pharmacokinetic (PK) parameter: Terminal half-life (t1/2) of CT-P59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>7. Pharmacokinetic (PK) parameter: Percentage of AUC0-inf obtained by extrapolation (%AUCext) of CT-P59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>8. Pharmacokinetic (PK) parameter: Terminal elimination rate constant (λz) of CT-P59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>9. Pharmacokinetic (PK) parameter: Total body clearance (CL) of CT-P59</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the Pharmacokinetics of CT-P59</measure>
    <time_frame>Up to Day 90</time_frame>
    <description>10. Pharmacokinetic (PK) parameter: Volume of distribution during the elimination phase (Vz) of CT-P59</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>SARS-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>Cohort 1 will receive a dose of CT-P59 or matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: CT-P59&#xD;
CT-P59 will be administered&#xD;
Drug: Placebo&#xD;
Placebo-matching CT-P59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 will receive a dose of CT-P59 or matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: CT-P59&#xD;
CT-P59 will be administered&#xD;
Drug: Placebo&#xD;
Placebo-matching CT-P59</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 will receive a dose of CT-P59 or matching placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: CT-P59&#xD;
CT-P59 will be administered&#xD;
Drug: Placebo&#xD;
Placebo-matching CT-P59</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CT-P59</intervention_name>
    <description>administered</description>
    <arm_group_label>Cohort 1 will receive a dose of CT-P59 or matching placebo</arm_group_label>
    <arm_group_label>Cohort 2 will receive a dose of CT-P59 or matching placebo</arm_group_label>
    <arm_group_label>Cohort 3 will receive a dose of CT-P59 or matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each patient must meet all of the following criteria to be randomized in this study:&#xD;
&#xD;
          1. Adult male or female patient, aged between 18 to 60 years (both inclusive).&#xD;
&#xD;
          2. Patient with laboratory confirmed SARS-CoV-2 infection by Reverse Transcription&#xD;
             Polymerase Chain Reaction (RT-PCR) at Screening.&#xD;
&#xD;
          3. Patient has mild conditions meeting all of the following criteria:&#xD;
&#xD;
               1. Oxygen saturation ≥ 94% on room air.&#xD;
&#xD;
               2. Not requiring supplemental oxygen.&#xD;
&#xD;
          4. Onset of symptom is no more than 7 days prior to the study drug administration.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Patient with severe condition meeting one of the following:&#xD;
&#xD;
          1. Respiratory distress with respiratory rate ≥ 30 breaths/min.&#xD;
&#xD;
          2. Requires supplemental oxygen.&#xD;
&#xD;
          3. Experience shock.&#xD;
&#xD;
          4. Complicated with other organs failure, and intensive care unit monitoring treatment is&#xD;
             needed by investigator's discretion.&#xD;
&#xD;
          5. Any other conditions suspected of being severe symptoms of SARS-CoV-2 infection, in&#xD;
             the opinion of the investigator, including but not limited to radiographic findings in&#xD;
             lung.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Incheon Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2020</study_first_posted>
  <last_update_submitted>October 18, 2020</last_update_submitted>
  <last_update_submitted_qc>October 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

